Daiichi Pharmaceuticals Subscribes to Gene Logic's BioExpress.

Business Editors/Health & Medical Writers

BIOWIRE2K

GAITHERSBURG, Md. and TOKYO--(BW HealthWire)--March 18, 2002

Gene Logic Inc. (Nasdaq: GLGC), a leading provider of genomics-based information products and services, today announced that Daiichi Pharmaceuticals Co., Ltd. ("Daiichi"), a global pharmaceutical company headquartered in Japan, has subscribed to Gene Logic's for use in its drug discovery and development efforts.

Financial terms of the multi-year subscription were not disclosed.

Under terms of the subscription agreement, Daiichi's global researchers will access the BioExpress(TM) product, which will be applied directly to Daiichi's internal target identification and target validation initiatives.

BioExpress(TM) consists of comprehensive genomic and clinical information derived from a broad range of normal and diseased human tissues, tissues from model animal systems and human and animal cell lines. The subscription agreement provides for broad deployment of BioExpress(TM) information and its related bioinformatics interface, the GeneExpress(R) Software System, used for data mining, analysis, indexing and visualization, across Daiichi's global research and development infrastructure.

As with all GeneExpress(R) subscription agreements, Daiichi will receive periodic content and software updates, as well as ongoing training and customer support to keep pace with Gene Logic's drive for continuous content growth and software technology development associated with its GeneExpress(R) product line.

Commenting on the subscription agreement, David S. Murray, Senior Vice President for Marketing and Sales for Gene Logic said, "We are very pleased to begin a long-term business relationship with Daiichi Pharmaceuticals. It is our goal to provide Daiichi scientists with leading research capabilities to enable and support their ongoing drug discovery and development initiatives." Continuing, Murray added, "We are encouraged by our expanding presence in Japan and look forward to continuing to work with our valued Japanese pharmaceutical customers."

Amersham Biosciences K.K., Gene Logic's sales and marketing partner in Japan, played a key role in facilitating Daiichi's subscription to the BioExpress(TM). "Our collaboration in Japan with Gene Logic has been very successful, as we continue to leverage our well-established presence in-country. This particular deal also further strengthens Amersham and Daiichi's existing relationship. As a leading provider of biotechnology systems, products and services for genomic research, Amersham is enthusiastic about facilitating this and future collaborations between Japanese-based pharmaceutical companies and Gene Logic," stated Kazuo Takeuchi, Vice President at Amersham Biosciences K.K. in Tokyo.

Daiichi Overview

Daiichi Pharmaceutical Co., Ltd. is one of the leading pharmaceutical companies based in Japan, renowned for its worldwide development and distribution of its original new quinolone antibiotics, anti-cancer chemotherapeutics and cardiovascular products.

The company places strong emphasis on genomic drug discovery and proteomics in its main therapeutic areas of research, such as "infectious diseases", "cancer" and "antithrombotic & cardiovascular", while creating and expanding its overseas bases for clinical development, sales and marketing of its new original products in North America, Europe and China, in order to be an R&D-driven global pharmaceutical company by 2006.

For more information about Daiichi Pharmaceutical Co. Ltd., visit the Company's Web site at http://www.daiichipharm.co.jp/index2.html.

Gene Logic Overview

Gene Logic Inc. is a leading genomics-based biocontent and bioinformatics company focused on developing information products related to gene activity in human disease and toxicity to optimize rapid, reliable and cost-effective pharmaceutical and biotechnology research and development.

Through its expertise in biosamples, high-throughput genomics technologies and data management and software development, the Company has developed a broad line of genomic information products and services based on its core database product, GeneExpress(R). For more information about Gene Logic, visit the Company's Web site at www.genelogic.com or telephone toll-free - 1/800/GENELOGIC.

Amersham Biosciences Overview

Amersham Biosciences, the life sciences business of Nycomed Amersham plc (LSE: NAM; NYSE: NYE), is a leading global provider of biotechnology systems, products and services for research into genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals.

The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies and research and academic institutions in North America, Europe, Latin America and Asia.

These statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in this press release.

These risks and uncertainties include, but are not limited to, the extent of utilization of genomic information by the pharmaceutical and biotechnology industries in research and product development, our ability to retain existing and obtain additional database customers in a timely manner, risks relating to the development of genomic database products and their use by existing and potential customers and ultimate consumers, our reliance on Affymetrix, Inc. for GeneChip(R) microarrays and other sole source suppliers, our ability to limit our losses and become profitable, our ability to timely supply customers with customized and new products, continued access to necessary human and animal tissue samples, the impact of technological advances and competition, our ability to enforce our intellectual property rights, and the impact of intellectual property rights of others, as well as other risks and uncertainties included in our Annual Report on Form 10-K for the year ended December 31, 2000 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.